BL
BLGO.US BioLargo Inc
- Market cap
- USD 23.4M
- P/E
- -
- P/B
- 18.69x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is BLGO.US undervalued?
Graham numberThe Graham number of BioLargo Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
BioLargo Inc fundamental analysis
No fundamental analysis for BioLargo Inc yet.
BioLargo Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About BioLargo Inc
BioLargo, Inc. invents, develops, and commercializes various platform technologies in the United States. The company's technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances (PFAS) water contamination; advanced water and wastewater treatment; industrial odor and volatile organic compounds control, air quality control, and infection control; and myriad environmental remediation. It provides full-service environmental engineering, …
Full company profileBioLargo Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
BioLargo Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 281K | 516K | 1.36M | 1.86M | 2.43M | 2.53M | 5.88M | 12.2M | 17.8M | 7.77M | 4.73M |
| Gross Profit | 175K | 193K | 621K | 916K | 1.23M | 1.10M | 2.86M | 6.15M | 7.85M | 3.41M | 2.27M |
| Operating Income | -4.93M | -5.90M | -6.18M | -6.42M | -7.34M | -6.32M | -5.12M | -4.16M | -4.31M | -10.9M | -13.9M |
| EBITDA | - | -5.65M | -7.15M | -7.38M | -7.72M | -6.64M | -5.03M | -4.29M | -4.02M | -14.2M | -13.4M |
| Net Income | -7.84M | -9.12M | -10.2M | -10.7M | -8.43M | -7.08M | -4.47M | -3.50M | -2.40M | -11.8M | -10.1M |
| EPS | - | -0.09 | -0.07 | -0.06 | -0.04 | -0.03 | -0.02 | -0.01 | -0.01 | -0.04 | -0.03 |
| Balance Sheet | |||||||||||
| Total Assets | 2.11M | 1.50M | 3.19M | 3.62M | 4.94M | 3.02M | 4.86M | 8.21M | 10.5M | 8.31M | 6.67M |
| Total Liabilities | 2.88M | 4.91M | 4.31M | 5.80M | 5.18M | 2.09M | 2.85M | 4.00M | 4.46M | 6.79M | 9.40M |
| Shareholders' Equity | -770K | -3.41M | -1.12M | -2.18M | -235K | 933K | 2.01M | 4.20M | 6.06M | 1.53M | -1.85M |
| Cash & Short-term Investments | 0.00 | 0.00 | 0.00 | 655K | 716K | 962K | 1.85M | 3.54M | 3.55M | 3.88M | 2.19M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.72M | -4.28M | -3.89M | -4.42M | -4.15M | -3.94M | -2.76M | -2.32M | -3.21M | -8.30M | -11.9M |
| Capital Expenditure | 61.9K | 29.0K | 58.0K | 35.0K | 23.0K | 21.0K | 271K | 439K | 1.24M | 46.0K | 384K |
| Free Cash Flow | - | -4.31M | -3.95M | -4.46M | -4.18M | -3.97M | -3.03M | -2.76M | -4.44M | -8.34M | -12.3M |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | -758.8% | -222.4% | -83.4% | -39.7% | -772.0% | - |
| ROA | -371.1% | -609.7% | -320.9% | -295.2% | -170.6% | -234.2% | -92.1% | -42.7% | -22.8% | -141.7% | -151.5% |
| Net Profit Margin | -2,788.9% | -1,766.2% | -749.3% | -574.4% | -346.7% | -279.7% | -76.0% | -28.7% | -13.5% | -151.7% | -213.8% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
BioLargo Inc dividends
BioLargo Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:25 on Mar 21, 2007.
Who owns BioLargo Inc
- Insiders 13.85%
- Institutions 0.04%
- Public & others 86.12%
- Shares outstanding 335M
- Free float 283M
BioLargo Inc company profile
- Company name
- BioLargo Inc
- Ticker
- BLGO.US
- Exchange
- USA Stocks
- Listed since
- Dec 12, 1991
- Sector
- Basic Materials
- Industry
- Chemicals
- Employees
- 44
- Fiscal year end
- December
- Address
- 14921 Chestnut Street, Westminster, CA, United States, 92683
- Phone
- 888 400 2863
- Website
- biolargo.com
About BioLargo Inc
BioLargo, Inc. invents, develops, and commercializes various platform technologies in the United States. The company's technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances (PFAS) water contamination; advanced water and wastewater treatment; industrial odor and volatile organic compounds control, air quality control, and infection control; and myriad environmental remediation. It provides full-service environmental engineering, battery energy storage, and advanced antimicrobial medical device platforms. BioLargo, Inc. is based in Westminster, California.
BioLargo Inc management
8- Mr. Dennis P. CalvertChairman, President & CEO · born 1963
- Mr. Charles K. Dargan II, C.F.A.Chief Financial Officer · born 1955
- Mr. Joseph L. ProvenzanoExecutive VP of Operations, Corporate Secretary & Director · born 1969
- Mr. Kenneth Reay CodeChief Science Officer & Director · born 1947
- Mr. Steven V. Harrison IIPresident of Clyra Medical Technologies Inc · born 1959
- Mr. Randall MoorePresident of BioLargo Engineering, Science & Technologies, LLC
- Dr. Richard Smith Ph.D.President of BioLargo Water
- Ms. Tonya ChandlerPresident of BioLargo Equipment Solutions & Technologies